Ligand Pharmaceuticals completed the acquisition of XOMA Royalty for ~$739 million, expanding its portfolio to over 200 royalty assets. The deal is expected to be immediately accretive and add exposure to major commercial products.
Ligand Pharmaceuticals completed the acquisition of XOMA Royalty for ~$739 million, expanding its portfolio to over 200 royalty assets. The deal is expected to be immediately accretive and add exposure to major commercial products.